Table 1.
Clinical and laboratory characteristics of the 63 study participants
| Sample | Sex | Age (y) | Diagnosis | Serum CA19‐9 (kU/L) | Serum CEA (kU/L) | TNM cancer stage |
|---|---|---|---|---|---|---|
| 1 | M | 75 | Healthy | 14 | 3.7 | |
| 2 | M | 64 | Healthy | 14 | 1.7 | |
| 3 | F | 65 | Healthy | 18 | 2 | |
| 4 | F | 81 | Healthy | 4 | 1.5 | |
| 5 | M | 48 | Healthy | 4 | 0.2 | |
| 6 | F | 69 | Healthy | 5 | 0.7 | |
| 7 | F | 70 | Healthy | N/A | N/A | |
| 8 | M | 67 | Healthy | 13 | 2.1 | |
| 9 | M | 80 | Healthy | 12 | 2.4 | |
| 10 | F | 74 | Healthy | 23 | 2.4 | |
| 11 | F | 69 | Healthy | 6 | 1.4 | |
| 12 | F | 65 | Healthy | 11 | 1.3 | |
| 13 | M | 68 | Healthy | 10 | 1.9 | |
| 14 | M | 74 | Healthy | 13 | 3.2 | |
| 15 | M | 82 | Healthy | 12 | 2.4 | |
| 16 | F | 44 | Healthy | 13 | 0.3 | |
| 17 | M | 82 | Healthy | 15 | 2.1 | |
| 18 | F | 80 | Healthy | 7 | 2.4 | |
| 19 | M | 80 | Healthy | 13 | 5.5 | |
| 20 | F | 77 | Healthy | 6 | 2.2 | |
| 21 | F | 59 | Healthy | 10 | 1 | |
| Median (IQR) | 72 (66.5) | 12.0 (6.8) | 2.1 (1.4) | |||
| 22 | F | 80 | IPMN | 1 | 4.4 | |
| 23 | F | 67 | IPMN | 5 | 2.9 | |
| 24 | F | 68 | IPMN | 8 | 1.6 | |
| 25 | M | 76 | IPMN | 1 | 4.3 | |
| 26 | M | 80 | IPMN | 5 | 0.4 | |
| 27 | M | 69 | IPMN | N/A | N/A | |
| 28 | M | 79 | IPMN | 1 | 2.6 | |
| 29 | M | 58 | IPMN | 8 | 5.5 | |
| 30 | F | 71 | IPMN | 2 | 4.5 | |
| 31 | M | 62 | IPMN | N/A | N/A | |
| 32 | F | 75 | IPMN | N/A | N/A | |
| 33 | F | 70 | IPMN | 5 | 2 | |
| 34 | F | 58 | IPMN | 71 | 2.7 | |
| 35 | F | 61 | IPMN | 1 | 2.8 | |
| 36 | F | 87 | IPMN | 20 | 6.9 | |
| 37 | F | 70 | IPMN | 7 | 2.6 | |
| 38 | F | 86 | IPMN | 13 | 4.1 | |
| 39 | F | 70 | IPMN | 9 | 0.8 | |
| 40 | F | 64 | IPMN | 10 | 5.3 | |
| 41 | F | 71 | IPMN | 9 | 2.4 | |
| 42 | M | 82 | IPMN | 10 | 2.3 | |
| 43 | M | 70 | IPMN | N/A | 3.4 | |
| Median (IQR) | 70 (66.3) | 7.5 (2.8) | 2.8 (2.4) | |||
| 44 | F | 74 | PDAC | 224 | 1.3 | T3N0M0 |
| 45 | M | 68 | PDAC | 5673 | 1.7 | T3N1M1 |
| 46 | M | 62 | PDAC | 31 809 | 196.4 | T4N1M1 |
| 47 | M | 62 | PDAC | 319 754 | 378.3 | T4N1M1 |
| 48 | F | 67 | PDAC | 9 | 0.9 | T3N0M0 |
| 49 | F | 86 | PDAC | 245.4 | 1.6 | T3N0M0 |
| 50 | F | 63 | PDAC | 96 | 4.4 | T4N1M0 |
| 51 | F | 86 | PDAC | 2 | 18.2 | T4N1M1 |
| 52 | F | 71 | PDAC | 138 | 1.8 | T4N1M0 |
| 53 | F | 86 | PDAC | 2768 | 1.8 | T4N1M1 |
| 54 | M | 65 | PDAC | 1423 | 29.9 | T3N1M1 |
| 55 | F | 78 | PDAC | 1924 | 8.4 | T3N1M1 |
| 56 | F | 65 | PDAC | 219 | 1.4 | T4N1M0 |
| 57 | F | 84 | PDAC | 66 | 1.5 | T3N1M0 |
| 58 | F | 68 | PDAC | 85 | 1.9 | T3N1M1 |
| 59 | F | 73 | PDAC | 1801 | 2.2 | T3N0M0 |
| 60 | M | 57 | PDAC | 2145 | 2.8 | T4N1M1 |
| 61 | M | 80 | PDAC | 14 | 2.8 | T3N1M1 |
| 62 | M | 74 | PDAC | 10 | 1.4 | T3N0M0 |
| 63 | M | 66 | PDAC | 223 713 | 3.7 | T4N1M1 |
| Median (IQR) | 69.5 (65) | 234.7 (80.3) | 2.1 (1.6) |
Median and interquartile range (IQR) of each group are indicated.
Abbreviations: CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; F, female; Healthy, healthy individual; IPMN, intraductal papillary mucinous neoplasm; M, male; PDAC, pancreatic ductal adenocarcinoma.